pour info

0820 GMT [Dow Jones] Teva Pharmaceuticals (TEVA) earlier-than-expected launch of its generic version of AstraZeneca´s (AZN) Pulmicort drug will force downgrades, an analyst says. Adds the worst-case-scenario forecasts a 10% downgrade of ´09 EPS estimates if AstraZeneca loses all its ´09 Plumicort sales. But says a more realistic downgrade takes into account AZN retaining 20% of market share at full price, with Teva taking 60% and Par Pharmaceutical (PRX) 20%. His initial estimates see ´08 EPS downgrades by about 3.7%, ´09 by 4.5% and ´10 by 2.1%. Adds it´s unclear if AstraZeneca´s temporary restraining order on Teva´s generic Pulmicort will be enforceable. AstraZeneca shares -2.4% at 2441p. (KAV)